Malignant Esophageal Neoplasm — Trials

Malignant Esophageal Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

1,926 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 518
Recruiting: 302
Ph III recruiting: 41
Growth YoY: +2.4%
Industry share: 23%
Top sponsor: National Cancer Institute (NCI)
Termination share: 28.5%
Trials / 1,000 deaths: 32.3 USA 2023 cdc-uscs

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (169)

clinicaltrialsPublishedShowing 151–200 of 365 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05432193	FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; A Dose Escalation Study for TReatment of Patients With Select Solid Tumors (FRONTIER)	terminated	Phase 1	20	POINT Biopharma, a wholly owned subsidiary of Eli Lilly and CompanyINDUSTRY	2	Jun 25, 2025	clinicaltrials
NCT07034118	Definitive Proton Radiotherapy Combined With Chemotherapy and Immunotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Phase I Clinical Study	not yet recruiting	Phase 1	23	Anhui Provincial Hospital